Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

TTAM Research Institute - 23andMe's co-founder and former CEO Anne Wojcicki's new company - is the winner in a final round of ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

A nonprofit led by the co-founder of genetic testing company 23andMe has won a bid to purchase the company, which declared bankruptcy in March.

Oklahoma Attorney General Gentner Drummond and attorneys general from 27 other states sue to block the sale of customer ...

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a delay, and more.